Skip to main content
SpringerLink
Log in

Konservative Therapie der Adipositas

Non-surgical therapy of obesity

  • Übersichten
  • Published:
Somnologie Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die Prävalenz der Adipositas ist in den letzten Jahren stetig angestiegen. Adipositas stellt als chronische Krankheit weltweit ein Gesundheitsproblem dar und ist mit einer Vielzahl von Komorbiditäten wie beispielsweise Typ 2 Diabetes mellitus assoziiert.

Ziel der Arbeit

Die vorliegende Arbeit gibt eine Übersicht über die Möglichkeiten und Grenzen der konservativen Therapie bei Adipositas. Zudem werden die Ursachen für die Adipositasentwicklung und die Assoziation von Adipositas und schlafbezogenen Atmungsstörungen (SBAS) erläutert.

Material und Methoden

Es wurde Literatur zusammengefasst, die sich der konservativen Adipositastherapie in Form von Ernährungs‑, Bewegungs- und Verhaltenstherapie sowie medikamentöser Therapie widmet. Zudem wurde eine Vielzahl von experimentellen Studien zitiert, welche Grundlagenwissen in diesem Themenbereich liefern.

Ergebnisse und Diskussion

Aufgrund der Komplexität der Pathogenese der Adipositas muss konservative Adipositastherapie auf einem multifaktoriellen Ansatz bestehen. Die Grundbausteine sind eine Ernährungs‑, Bewegungs- und Verhaltenstherapie. Bei nicht ausreichender Gewichtsreduktion kann eine zusätzliche medikamentöse Therapie indiziert sein.

Abstract

Background

Obesity as a chronic disease leads to several adverse metabolic comorbidities like type 2 diabetes mellitus and its prevalence has increased continuously over the last decades.

Objectives

The aim of this work is to present an overview of the possibilities and limitations of non-surgical therapy for patients with obesity. Furthermore, it explains the development of obesity as well as the association between sleep-related breathing disorders and obesity.

Materials and methods

Literature and guidelines focusing on non-surgical therapy of obesity, i. e. diet, physical activity and behavior, were screened. Furthermore, data on several experimental studies regarding the weight-lowering effects of drugs were included.

Results and discussion

Due to the complexity of the pathogeneses of obesity, the therapy should base on a multifactorial approach, consisting of nutritional and physical activity counselling and behavioral therapy. If this “basic” program is not effective the use of weight-lowering drugs could be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Bazzano LA, Hu T, Reynolds K et al (2014) Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med 161:309–318

    Article  PubMed  PubMed Central  Google Scholar 

  2. Berg A, Bischoff S, Colombo-Benkmann M (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Prävention und Therapie der AdipositasInterdisziplinäre Leitlinie der Qualität S3 zur Prävention und Therapie der Adipositas. http://www.awmf.org/leitlinien/detail/ll/050-001.html. Zugegriffen: 20. Dez. 2017

    Google Scholar 

  3. Blackman A, Foster GD, Zammit G et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes 2005(40):1310–1319

    Article  Google Scholar 

  4. Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124–132

    Article  PubMed  CAS  Google Scholar 

  5. Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S et al (2015) Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS ONE 10:e117808

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757

    Article  PubMed  CAS  Google Scholar 

  7. DePaoli AM (2014) 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 223:T71–81

    Article  PubMed  CAS  Google Scholar 

  8. Elbelt U (2016) Ätiologie der Adipositas. In: Suttorp N, Möckel M, Siegmund B, Dietel M (Hrsg) Harrisons Innere Medizin. ABW Wissenschaftsverlagsgesellschaft, Berlin

    Google Scholar 

  9. Ellrichmann M, Kapelle M, Ritter PR et al (2008) Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 93:3995–3998

    Article  PubMed  CAS  Google Scholar 

  10. European Medicines Agency (2013) Refusal of the marketing authorisation for Qsiva. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf. Zugegriffen: 20. Dez. 2017

    Google Scholar 

  11. Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884

    Article  PubMed  CAS  Google Scholar 

  12. Greenway FL, Fujioka K, Plodkowski RA et al (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595–605

    Article  PubMed  CAS  Google Scholar 

  13. Hemmingsson E, Johansson K, Eriksson J et al (2012) Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study. Am J Clin Nutr 96:953–961

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Howard ME, Piper AJ, Stevens B et al (2017) A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax 72:437–444

    Article  PubMed  Google Scholar 

  15. Johnston BC, Kanters S, Bandayrel K et al (2014) Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 312:923–933

    Article  PubMed  CAS  Google Scholar 

  16. Khera R, Murad MH, Chandar AK et al (2016) Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315:2424–2434

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470–512

    Article  PubMed  CAS  Google Scholar 

  18. Kluge M, Schüssler P, Bleninger P et al (2008) Ghrelin alone or co-administered with GHRH or CRH increases non-REM sleep and decreases REM sleep in young males. Psychoneuroendocrinology 33:497–506

    Article  PubMed  CAS  Google Scholar 

  19. Lean ME, Han TS, Morrison CE (1995) Waist circumference as a measure for indicating need for weight management. BMJ 311:158–161

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Macavei VM, Spurling KJ, Loft J, Makker HK (2013) Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med 9:879–884

    PubMed  PubMed Central  Google Scholar 

  21. Marino AB, Cole SW, Nuzum DS (2014) Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 71:223–226

    Article  PubMed  CAS  Google Scholar 

  22. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Masa JF, Corral J, Caballero C et al (2016) Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax 71:899–906

    Article  PubMed  Google Scholar 

  24. Mayer G, Arzt M, Braumann B et al (2017) S3-Leitlinie – Nicht erholsamer Schlaf/Schlafstörungen. Somnologie (Berl) 20:97–180

    Article  Google Scholar 

  25. McTigue KM, Harris R, Hemphill B et al (2003) Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139:933–949

    Article  PubMed  Google Scholar 

  26. Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Olson AL, Zwillich C (2005) The obesity hypoventilation syndrome. Am J Med 118:948–956

    Article  PubMed  Google Scholar 

  28. Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11–22

    Article  PubMed  CAS  Google Scholar 

  29. Redolfi S, Corda L, La Piana G et al (2007) Long-term non-invasive ventilation increases chemosensitivity and leptin in obesity-hypoventilation syndrome. Respir Med 101:1191–1195

    Article  PubMed  Google Scholar 

  30. Roberts C, Troop N, Connan F et al (2007) The effects of stress on body weight: biological and psychological predictors of change in BMI. Obesity (Silver Spring) 15:3045–3055

    Article  Google Scholar 

  31. Schienkiewitz A, Mensink G, Kuhnert R, Lange C (2018) Übergewicht und Adipositas bei Erwachsenen in Deutschland. http://edoc.rki.de/oa/articles/res0ogkgy5fA/PDF/21AXYyB7Gu0mo.pdf. Zugegriffen: 20. Dez. 2017

    Google Scholar 

  32. Schmid SM, Hallschmid M, Schultes B (2015) The metabolic burden of sleep loss. Lancet Diabetes Endocrinol 3:52–62

    Article  PubMed  CAS  Google Scholar 

  33. Shai I, Schwarzfuchs D, Henkin Y et al (2008) Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 359:229–241

    Article  PubMed  CAS  Google Scholar 

  34. Sharfstein JM, Psaty BM (2016) Evaluation of the cardiovascular risk of naltrexone-bupropion: a study interrupted. JAMA 315:984–986

    Article  PubMed  CAS  Google Scholar 

  35. Sharma AM, Padwal R (2010) Obesity is a sign—over-eating is a symptom: an aetiological framework for the assessment and management of obesity. Obesity (Silver Spring) 11:362–370

    CAS  Google Scholar 

  36. Sherman MM, Ungureanu S, Rey JA (2016) Naltrexone/Bupropion ER (contrave): newly approved treatment option for chronic weight management in obese adults. P T 41:164–172

    PubMed  PubMed Central  Google Scholar 

  37. Sjöström L, Rissanen A, Andersen T et al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352:167–172

    Article  PubMed  Google Scholar 

  38. Sturm R (2007) Increases in morbid obesity in the USA: 2000–2005. Public Health 121:492–496

    Article  PubMed  CAS  Google Scholar 

  39. Swift DL, Johannsen NM, Lavie CJ et al (2014) The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis 56:441–447

    Article  PubMed  Google Scholar 

  40. Verbraecken J, McNicholas WT (2013) Respiratory mechanics and ventilatory control in overlap syndrome and obesity hypoventilation. Respir Res 14:132

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Universität zu Lübeck, Ratzeburger Alle 160, 23538, Lübeck, Deutschland

    Svenja Meyhöfer,  Hannes Kalscheuer,  Britta Wilms &  Sebastian M. Schmid

  2. Deutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Deutschland

    Svenja Meyhöfer,  Britta Wilms &  Sebastian M. Schmid

  3. Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universität zu Lübeck, Lübeck, Deutschland

    Armin Steffen

Authors
  1. Svenja Meyhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Armin Steffen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hannes Kalscheuer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Britta Wilms
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sebastian M. Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian M. Schmid.

Ethics declarations

Interessenkonflikt

S. Meyhöfer, A. Steffen, H. Kalscheuer, B. Wilms und S.M. Schmid geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meyhöfer, S., Steffen, A., Kalscheuer, H. et al. Konservative Therapie der Adipositas. Somnologie 22, 106–111 (2018). https://doi.org/10.1007/s11818-018-0159-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11818-018-0159-3

Schlüsselwörter

Keywords

Search

Navigation